Monitor the company's upcoming proxy filing for the 2026 annual meeting to see if a replacement is named and for any changes in committee composition. No immediate financial impact is expected from this routine board transition.
SCYX drugs
SCYX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 21 $8.48entry
- T+1 · 7mo ago −2.83%α −3.84% · $8.24
- T+5 · 7mo ago −6.98%α −8.06% · $7.89
- T+20 · 6mo ago −38.02%α −42.23% · $5.26
- T+60 · 4mo ago −47.17%α −54.07% · $4.48
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Steven C. Gilman, a board member of SCYNEXIS Inc., notified the company of his intent to retire and not stand for re-election at the 2026 annual meeting. His departure is due to retirement and not related to any disagreement with the company.
Key Facts
- Dr. Steven C. Gilman is retiring from the Board of Directors and will not stand for re-election at the 2026 annual meeting.
- His term ends upon the conclusion of the 2026 Annual Meeting; he will remain Chair of the Compensation Committee and a member of the Nominating and Corporate Governance Committee until then.
- The company stated the resignation was not due to any disagreement with management, operations, or strategy.
Financial Impact
No direct financial impact disclosed.
Risk Factors
- Potential loss of institutional knowledge given Dr. Gilman's roles as Chair of the Compensation Committee and member of the Nominating and Corporate Governance Committee.
- Governance continuity risk if replacements for key committee roles are not promptly disclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178253-26-000009 |
| Document: 0001178253-26-000009-index-headers.html | 0001178253-26-000009 |
| Document: 0001178253-26-000009-index.html | 0001178253-26-000009 |
| Document: 0001178253-26-000009.txt | 0001178253-26-000009 |
Track record
15 reports on SCYX
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +33.49% at T+20 after the May 11, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $2.91 Now $2.91 −0.00% settles Nov 24
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.91 Now $2.91 +0.00% settles Nov 24
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $3.81 to $3.86 Now $2.91 −23.62% ▲ +1.31% +0.61% vs SPY
- Oct 6, 20265w ago Press Release Neutral 4/10 Entry $4.84 to $3.99 Now $2.91 −39.88% ▼ −17.56% −17.42% vs SPY
- Sep 28, 20267w ago Press Release Bullish 6/10 Entry $4.62 to $5.03 Now $2.91 −37.01% ▲ +8.87% +7.67% vs SPY
- Sep 22, 20267w ago 8-K Neutral 2/10 Entry $4.86 to $4.66 Now $2.91 −40.12% ▼ −4.12% −2.93% vs SPY
- Sep 10, 20269w ago 8-K Neutral 2/10 Entry $4.70 to $4.45 Now $2.91 −38.09% ▼ −5.32% −4.82% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $3.87 to $4.73 Now $2.91 −24.81% ▲ +22.22% +20.83% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers